Erratum: Gadolinium-based contrast agents for magnetic resonance cancer imaging [WIREs Nanomed Nanobiotechnol 5 (2013) 1-18] doi: 10.1002/wnan.1198;Gadolinium-based contrast agents for magnetic resonance cancer imaging

Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology

Volumn 5, Issue 1, 2013, Pages 1-18

  Zhou, Zhuxian ^a   Lu, Zheng Rong ^a  

^a Case Western Reserve University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMICAL MODIFICATION; DISEASES; MAGNETIC RESONANCE IMAGING; MEDICAL IMAGING; TOXICITY; TUMORS;

CANCER GENOMICS; DESIGN AND DEVELOPMENT; FUNCTIONAL IMAGING; KINETIC STABILITY; MAGNETIC RESONANCE IMAGING (MRI); MRI CONTRAST AGENTS; PHARMACOKINETIC PROPERTIES; PHYSICOCHEMICAL PROPERTY;

GADOLINIUM COMPOUNDS;

ABLACAR; DEXTRAN GADOLINIUM PENTETATE; GADOBENATE DIMEGLUMINE; GADODIAMIDE; GADOFOSVESET; GADOLINIUM; GADOLINIUM CHELATE; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE; GADOMELITOL; GADOMER 17; GADOTERATE MEGLUMINE; GADOTERIC ACID; GADOTERIDOL; GADOXETIC ACID; UNCLASSIFIED DRUG;

BLOOD BRAIN BARRIER; CANCER DIAGNOSIS; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; HUMAN; IN VIVO STUDY; MAGNETIC RESONANCE IMAGING UNIT; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 84871659077     PISSN: 19395116     EISSN: 19390041     Source Type: Journal    
DOI: 10.1002/wnan.1214     Document Type: Erratum

References (96)

1. Lauffer RB. Paramagnetic metal-complexes as water proton relaxation agents for NMR Imaging-theory and design. Chem Rev 1987, 87:901-927.
2. Caravan P, Ellison JJ, McMurry TJ, Lauffer RB. Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications. Chem Rev 1999, 99: 2293-2352.
3. Damadian R. Tumor detection by nuclear magnetic resonance. Science 1971, 171:1151-1153.
4. Werner EJ, Datta A, Jocher CJ, Raymond KN. High-relaxivity MRI contrast agents: where coordination chemistry meets medical imaging. Angew Chem Int Ed 2008, 47:8568-8580.
5. Caravan P. Strategies for increasing the sensitivity of gadolinium based MRI contrast agents. Chem Soc Rev 2006, 35:512-523.
6. Villaraza AJL, Bumb A, Brechbiel MW. Macromolecules, dendrimers, and nanomaterials in magnetic resonance imaging: the interplay between size, function, and pharmacokinetics. Chem Rev 2010, 110: 2921-2959.
7. Aime S, Crich SG, Gianolio E, Giovenzana GB, Tei L, Terreno E. High sensitivity lanthanide(III) based probes for MR-medical imaging. Coord Chem Rev 2006, 250: 1562-1579.
8. Kamaly N, Miller AD, Bell JD. Chemistry of tumour targeted T1 based MRI contrast agents. Curr Top Med Chem 2010, 10:1158-1183.
9. Gore JC, Manning HC, Quarles CC, Waddell KW, Yankeelov TE. Magnetic resonance in the era of molecular imaging of cancer. Magn Reson Imaging 2011, 29: 587-600.
10. Glunde K, Artemov D, Penet MF, Jacobs MA, Bhujwalla ZM. Magnetic resonance spectroscopy in metabolic and molecular imaging and diagnosis of cancer. Chem Rev 2010, 110:3043-3059.
11. Caravan P, Cloutier NJ, Greenfield MT, McDermid SA, Dunham SU, Bulte JW, Amedio JC, Jr., Looby RJ, Supkowski RM, Horrocks WD, Jr. et al. The interaction of MS-325 with human serum albumin and its effect on proton relaxation rates. J Am Chem Soc 2002, 124: 3152-3162.
12. Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weinmann HJ. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol 2005, 40:715-724.
13. Lansman JB. Blockade of current through single calcium channels by trivalent lanthanide cations-effect of ionic radius on the rates of ion entry and exit. J Gen Physiol 1990, 95:679-696.
14. Biagi BA, Enyeart JJ. Gadolinium blocks low-threshold and high-threshold calcium currents in pituitary-cells. Am J Physiol 1990, 259:C515-C520.
15. Laurent S, Elst LV, Copoix F, Muller RN. Stability of MRI paramagnetic contrast media-a proton relaxometric protocol for transmetallation assessment. Invest Radiol 2001, 36:115-122.
16. Greenberg SA. Zinc transmetallation and gadolinium retention after MR imaging: case report. Radiology 2010, 257:670-673.
17. Thomsen HS. Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamide. Eur Radiol 2006, 16:2619-2621.
18. Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Del Rev 2011, 63: 131-135.
19. Weinmann HJ, Brasch RC, Press WR, Wesbey GE. Characteristics of gadolinium-DTPA complex-a potential NMR contrast agent. Am J Roentgenol 1984, 142: 619-624.
20. Wiener EC, Brechbiel MW, Brothers H, Magin RL, Gansow OA, Tomalia DA, Lauterbur PC. Dendrimer-based metal-chelates-a new class of magnetic-resonance-imaging contrast agents. Magn Reson Med 1994, 31: 1-8.
21. Perazella MA. Current status of gadolinium toxicity in patients with kidney disease. Clin J Am Soc Nephro 2009, 4:461-469.
22. Leach MO, Brindle KM, Evelhoch JL, Griffiths JR, Horsman MR, Jackson A, Jayson G, Judson IR, Knopp MV, Maxwell RJ, et al. Assessment of antiangiogenic and antivascular therapeutics using MRI: recommendations for appropriate methodology for clinical trials. Br J Radiol 2003, 76:S87-S91.
23. III-based MRI contrast agents. Eur J Inorg Chem 2012, 1945-1960.
24. 3+-relaxivities as a function of molecular-weight and conjugation efficiency. Magn Reson Imaging 1992, 10:913-917.
25. Port M, Corot C, Rousseaux O, Raynal I, Devoldere L, Idee JM, Dencausse A, Le Greneur S, Simonot C, Meyer D. P792: a rapid clearance blood pool agent for magnetic resonance imaging: preliminary results. Magn Reson Mater Phy Biol Med 2001, 12: 121-127.
26. Fries P, Runge VM, Bucker A, Schurholz H, Reith W, Robert P, Jackson C, Lanz T, Schneider G. Brain tumor enhancement in magnetic resonance imaging at 3 tesla intraindividual comparison of two high relaxivity macromolecular contrast media with a standard extracellular Gd-chelate in a rat brain tumor model. Invest Radiol 2009, 44:200-206.
27. Daldrup H, Shames DM, Wendland M, Okuhata Y, Link TM, Rosenau W, Lu Y, Brasch RC. Correlation of dynamic contrast-enhanced magnetic resonance imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media. Pediatr Radiol 1998, 28:67-78.
28. Ogan MD, Schmiedl U, Moseley ME, Grodd W, Paajanen H, Brasch RC. Albumin labeled with Gd-DTPA-an intravascular contrast-enhancing agent for magnetic-resonance blood pool imaging-preparation and characterization. Invest Radiol 1987, 22:665-671.
29. Schmiedl U, Ogan M, Paajanen H, Marotti M, Crooks LE, Brito AC, Brasch RC. Albumin labeled with Gd-DTPA as an intravascular, blood pool enhancing agent for MR imaging-biodistribution and imaging studies. Radiology 1987, 162:205-210.
30. Raatschen HJ, Simon GH, Fu YJ, Sennino B, Shames DM, Wendland MF, McDonald DM, Brasch RC. Vascular permeability during antiangiogenesis treatment: MR imaging assay results as biomarker for subsequent tumor growth in rats. Radiology 2008, 247:391-399.
31. Dafni H, Kim SJ, Bankson JA, Sankaranaravanapillai M, Ronen SM. Macromolecular dynamic contrast-enhanced (DCE)-MRI detects reduced vascular permeability in a prostate cancer bone metastasis model following anti-platelet-derived growth factor receptor (PDGFR) therapy, indicating a drop in vascular endothelial growth factor receptor (VEGFR) activation. Magn Reson Med 2008, 60:822-833.
32. Bhujwalla ZM, Artemov D, Natarajan K, Solaiyappan M, Kollars P, Kristjansen PEG. Reduction of vascular and permeable regions in solid tumors detected by macromolecular contrast magnetic resonance imaging after treatment with antiangiogenic agent TNP-470. Clin Cancer Res 2003, 9:355-362.
33. 3+ binding to model DTPA-conjugates and DTPA-proteins-implications for their use as magnetic-resonance contrast agents. Magn Reson Med 1988, 8: 180-190.
34. Baxter AB, Melnikoff S, Stites DP, Brasch RC. Immunogenicity of gadolinium-based contrast agents for magnetic-resonance-imaging-induction and characterization of antibodies in animals. Invest Radiol 1991, 26: 1035-1040.
35. Schuhmanngiampieri G, Schmittwillich H, Frenzel T, Press WR, Weinmann HJ. In vivo and in vitro evaluation of Gd-DTPA-polylysine as a macromolecular contrast agent for magnetic-resonance-imaging. Invest Radiol 1991, 26:969-974.
36. Curtet C, Maton F, Havet T, Slinkin M, Mishra A, Chatal JF, Muller RN. Polylysine-Gd-DTPAn and polylysine-Gd-DOTAn coupled to anti-CEA F(ab′)2 fragments as potential immunocontrast agents. Relaxometry, biodistribution, and magnetic resonance imaging in nude mice grafted with human colorectal carcinoma. Invest Radiol 1998, 33:752-761.
37. Vexler VS, Clement O, Schmittwillich H, Brasch RC. Effect of varying the molecular-weight of the MR contrast agent Gd-DTPA-polylysine on blood pharmacokinetics and enhancement patterns. J Magn Reson Imaging 1994, 4:381-388.
38. Wendland MF, Saeed M, Yu KK, Roberts TPL, Lauerma K, Derugin N, Varadarajan J, Watson AD, Higgins CB. Inversion-recovery EPI of bolus transit in rat myocardium using intravascular and extravascular gadolinium-based MR contrast-media-dose effects on peak signal enhancement. Magn Reson Med 1994, 32: 319-329.
39. Desser TS, Rubin DL, Muller HH, Qing F, Khodor S, Zanazzi G, Young SW, Ladd DL, Wellons JA, Kellar KE, et al. Dynamics of tumor imaging with Gd-DTPA polyethylene-glycol polymers-dependence on molecular-weight. J Magn Reson Imaging 1994, 4: 467-472.
40. Frank H, Weissleder R, Bogdanov AA, Brady TJ. Detection of pulmonary emboli by using MR-angiography with mPEG-Pl-GdDTPA-an experimental-study in rabbits. Am J Roentgenol 1994, 162:1041-1046.
41. Vanhecke P, Marchal G, Bosmans H, Johannik K, Jiang Y, Vogler H, Vanongeval C, Baert AL, Speck U. NMR imaging study of the pharmacodynamics of polylysine-gadolinium-DTPA in the rabbit and the rat. Magn Reson Imaging 1991, 9:313-321.
42. Wang SC, Wikstrom MG, White DL, Klaveness J, Holtz E, Rongved P, Moseley ME, Brasch RC. Evaluation of Gd-DTPA labeled dextran as an intravascular MR contrast agent-imaging characteristics in normal rat-tissues. Radiology 1990, 175:483-488.
43. 3+-diethylenetriaminepentaacetic acid and dextran. 2. Influence of spacer arm length and conjugate molecular mass on the paramagnetic properties and some biological parameters. Bioconjugate Chem 1998, 9:94-99.
44. Sirlin CB, Vera DR, Corbeil JA, Caballero MB, Buxton RB, Mattrey RF. Gadolinium-DTPA-dextran: a macromolecular MR blood pool contrast agent. Acad Radiol 2004, 11:1361-1369.
45. Armitage FE, Richardson DE, Li KCP. 1990, 1: 365-374.
46. Adam G, Neuerburg J, Spuntrup E, Muhler A, Scherer K, Gunther RW. Gd-DTPA-cascade-polymer-potential blood-pool contrast agent for MR-imaging. J Magn Reson Imaging 1994, 4:462-466.
47. Venditto VJ, Regino CAS, Brechbiel MW. PAMAM dendrimer based macromolecules as improved contrast agents. Mol Pharm 2005, 2:302-311.
48. Langereis S, de Lussanet QG, van Genderen MHP, Backes WH, Meijer EW. Multivalent contrast agents based on gadolinium-diethylenetriaminepentaacetic acid-terminated poly(propylene imine) dendrimers for magnetic resonance imaging. Macromolecules 2004, 37: 3084-3091.
49. Langereis S, de Lussanet QG, van Genderen MHP, Meijer EW, Beets-Tan RGH, Griffioen AW, van Engelshoven JMA, Backes WH. Evaluation of Gd(III)DTPA-terminated poly(propylene imine) dendrimers as contrast agents for MR imaging. NMR Biomed 2006, 19:133-141.
50. Luo K, Liu G, She WC, Wang QY, Wang G, He B, Ai H, Gong QY, Song B, Gu ZW. Gadolinium-labeled peptide dendrimers with controlled structures as potential magnetic resonance imaging contrast agents. Biomaterials 2011, 32:7951-7960.
51. Kobayashi H, Brechbiel MW. Dendrimer-based macromolecular MRI contrast agents: characteristics and application. Mol Imaging 2003, 2:1-10.
52. Kobayashi H, Brechbiel MW. Nano-sized MRI contrast agents with dendrimer cores. Adv Drug Del Rev 2005, 57:2271-2286.
53. Sato N, Kobayashi H, Hiraga A, Saga T, Togashi K, Konishi J, Brechbiel MW. Pharmacokinetics and enhancement patterns of macromolecular MR contrast agents with various sizes of polyamidoamine dendrimer cores. Magn Reson Med 2001, 46:1169-1173.
54. Kobayashi H, Sato N, Hiraga A, Saga T, Nakamoto Y, Ueda H, Konishi J, Togashi K, Brechbiel MW. 3D-micro-MR angiography of mice using macromolecular MR contrast agents with polyamidoamine dendrimer core with reference to their pharmacokinetic properties. Magn Reson Med 2001, 45:454-460.
55. Lu ZR, Mohs AM, Zong Y, Feng Y. Polydisulfide Gd(III) chelates as biodegradable macromolecular magnetic resonance imaging contrast agents. Int J Nanomed 2006, 1:31-40.
56. Lu ZR, Wu XM. Polydisulfide-based biodegradable macromolecular magnetic resonance imaging contrast agents. Isr J Chem 2010, 50:220-232.
57. Lu ZR, Parker DL, Goodrich KC, Wang X, Dalle JG, Buswell HR. Extracellular biodegradable macromolecular gadolinium(III) complexes for MRI. Magn Reson Med 2004, 51:27-34.
58. Zong YD, Wang XH, Goodrich KC, Mohs AM, Parker DL, Lu ZR. Contrast-enhanced MRI with new biodegradable macromolecular Gd(III) complexes in tumor-bearing mice. Magn Reson Med 2005, 53: 835-842.
59. Zong YD, Wang XL, Jeong EK, Parker DL, Lu ZR. Structural effect on degradability and in vivo contrast enhancement of polydisulfide Gd(III) complexes as biodegradable macromolecular MRI contrast agents. Magn Reson Imaging 2009, 27:503-511.
60. Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthay K, Huang SK, Lee KD, Woodle MC, Lasic DD, Redemann C, et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA 1991, 88:11460-11464.
61. Unger EC, Winokur T, MacDougall P, Rosenblum J, Clair M, Gatenby R, Tilcock C. Hepatic metastases: liposomal Gd-DTPA-enhanced MR imaging. Radiology 1989, 171:81-85.
62. Unger EC, Macdougall P, Cullis P, Tilcock C. Liposomal Gd-DTPA-effect of encapsulation on enhancement of hepatoma model by MRI. Magn Reson Imaging 1989, 7:417-423.
63. Bui T, Stevenson J, Hoekman J, Zhang SR, Maravilla K, Ho RJY. Novel Gd nanoparticles enhance vascular contrast for high-resolution magnetic resonance imaging. PLoS One 2010, 5:e13082.
64. Hak S, Sanders HMHF, Agrawal P, Langereis S, Grull H, Keizer HM, Arena F, Terreno E, Strijkers GJ, Nicolay K. A high relaxivity Gd(III)DOTA-DSPE-based liposomal contrast agent for magnetic resonance imaging. Eur J Pharm Biopharm 2009, 72:397-404.
65. Mulder WJM, Strijkers GJ, van Tilborg GAF, Griffioen AW, Nicolay K. Lipid-based nanoparticles for contrast-enhanced MRI and molecular imaging. NMR Biomed 2006, 19:142-164.
66. Tilcock C, Unger E, Cullis P, Macdougall P. Liposomal Gd-DTPA-preparation and characterization of relaxivity. Radiology 1989, 171:77-80.
67. Unger E, Shen D, Wu GL, Fritz T. Liposomes as MR contrast agents-pros and cons. Magn Reson Med 1991, 22:304-308.
68. Ghaghada KB, Ravoori M, Sabapathy D, Bankson J, Kundra V, Annapragada A. New dual mode gadolinium nanoparticle contrast agent for magnetic resonance imaging. PLoS One 2009, 4:e7628. pii.
69. Krauze MT, Forsayeth J, Park JW, Bankiewicz KS. Real-time imaging and quantification of brain delivery of liposomes. Pharm Res 2006, 23:2493-2504.
70. Mamot C, Nguyen JB, Pourdehnad M, Hadaczek P, Saito R, Bringas JR, Drummond DC, Hong KL, Kirpotin DB, McKnight T, et al. Extensive distribution of liposomes in rodent brains and brain tumors following convection-enhanced delivery. J Neurooncol 2004, 68: 1-9.
71. Karathanasis E, Park J, Agarwal A, Patel V, Zhao F, Annapragada AV, Hu X, Bellamkonda RV. MRI mediated, non-invasive tracking of intratumoral distribution of nanocarriers in rat glioma. Nanotechnology 2008, 19:315109.pp.
72. Saito R, Bringas JR, McKnight TR, Wendland MF, Mamot C, Drummond DC, Kirpotin DB, Park JW, Berger MS, Bankiewiez KS. Distribution of liposomes into brain and rat brain tumor models by convection-enhanced delivery monitored with magnetic resonance imaging. Cancer Res 2004, 64:2572-2579.
73. Park JA, Lee JJ, Jung JC, Yu DY, Oh C, Ha S, Kim TJ, Chang YM. Gd-DOTA conjugate of RGD as a potential tumor-targeting MRI contrast agent. ChemBioChem 2008, 9:2811-2813.
74. Pilch J, Brown DM, Komatsu M, Jarvinen TA, Yang M, Peters D, Hoffman RM, Ruoslahti E. Peptides selected for binding to clotted plasma accumulate in tumor stroma and wounds. Proc Natl Acad Sci USA 2006, 103: 2800-2804.
75. Ye FR, Jeong EK, Jia ZJ, Yang TX, Parker D, Lu ZR. A peptide targeted contrast agent specific to fibrin-fibronectin complexes for cancer molecular imaging with MRI. Bioconjugate Chem 2008, 19:2300-2303.
76. Ye FR, Jeong EK, Parker D, Lu ZR. Evaluation of CLT1-(Gd-DTPA) for MR molecular imaging in a mouse breast cancer model. Chin J Magn Reson Imaging 2011, 2:325-330.
77. Artemov D, Mori N, Ravi R, Bhujwalla ZM. Magnetic resonance molecular imaging of the HER-2/neu receptor. Cancer Res 2003, 63:2723-2727.
78. Artemov D. Molecular magnetic resonance imaging with targeted contrast agents. J Cell Biochem 2003, 90: 518-524.
79. Chen K, Xie J, Chen XY. RGD-human serum albumin conjugates as ffficient tumor targeting probes. Mol Imaging 2009, 8:65-73.
80. Qiao JJ, Li SY, Wei LX, Jiang J, Long R, Mao H, Wei L, Wang LY, Yang H, Grossniklaus HE, et al. HER2 targeted molecular MR imaging using a de novo designed protein contrast agent. PLoS One 2011, 6:e18103.
81. Paganelli G, Bartolomei M, Ferrari M, Cremonesi M, Broggi G, Maira G, Sturiale C, Grana C, Prisco G, Gatti M, et al. Pre-targeted locoregional radioimmunotherapy with 90Y-biotin in glioma patients: phase I study and preliminary therapeutic results. Cancer Biother Radiopharm 2001, 16:227-235.
82. Xu H, Regino CAS, Koyama Y, Hama Y, Gunn AJ, Bernardo M, Kobayashi H, Choyke PL, Brechbiel MW. Preparation and preliminary evaluation of a biotin-targeted, lectin-targeted dendrimer-based probe for dual-modality magnetic resonance and fluorescence Imaging. Bioconjugate Chem 2007, 18:1474-1482.
83. Huang RQ, Han L, Li JF, Liu SH, Shao K, Kuang YY, Hu X, Wang XX, Lei H, Jiang C. Chlorotoxin-modified macromolecular contrast agent for MRI tumor diagnosis. Biomaterials 2011, 32:5177-5186.
84. Han LA, Li JF, Huang SX, Huang RQ, Liu SH, Hu X, Yi PW, Shan D, Wang XX, Lei H, et al. Peptide-conjugated polyamidoamine dendrimer as a nanoscale tumor-targeted T1 magnetic resonance imaging contrast agent. Biomaterials 2011, 32:2989-2998.
85. Tan MQ, Wu XM, Jeong EK, Chen QJ, Lu ZR. Peptide-targeted nanoglobular Gd-DOTA monoamide conjugates for magnetic resonance cancer molecular imaging. Biomacromolecules 2010, 11:754-761.
86. Swanson SD, Kukowska-Latallo JF, Patri AK, Chen CY, Ge S, Cao ZY, Kotlyar A, East AT, Baker JR. Targeted gadolinium-loaded dendrimer nanoparticles for tumor-specific magnetic resonance contrast enhancement. Int J Nanomed 2008, 3:201-210.
87. Konda SD, Aref M, Wang S, Brechbiel M, Wiener EC. Specific targeting of folate-dendrimer MRI contrast agents to the high affinity folate receptor expressed in ovarian tumor xenografts. Magn Reson Mater Phys Biol Med 2001, 12:104-113.
88. Lucock M. Folic acid: nutritional biochemistry, molecular biology, and role in disease processes. Mol Genet Metab 2000, 71:121-138.
89. Lu YJ, Low PS. Folate targeting of haptens to cancer cell surfaces mediates immunotherapy of syngeneic murine tumors. Cancer Immunol Immun 2002, 51: 153-162.
90. 99mTc-EC20 for imaging folate receptor-positive tumors. J Nucl Med 2004, 45: 857-866.
91. Parker N, Turk MJ, Westrick E, Lewis JD, Low PS, Leamon CP. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem 2005, 338: 284-293.
92. Kamaly N, Kalber T, Thanou M, Bell JD, Miller AD. Folate receptor targeted bimodal liposomes for tumor magnetic resonance imaging. Bioconjugate Chem 2009, 20:648-655.
93. Vaccaro M, Accardo A, D'Errico G, Schillen K, Radulescu A, Tesauro D, Morelli G, Paduano L. Peptides and Gd complexes containing colloidal assemblies as tumor-specific contrast agents in MRI: physicochemical characterization. Biophys J 2007, 93:1736-1746.
94. Accardo A, Tesauro D, Roscigno P, Gianolio E, Paduano L, D'Errico G, Pedone C, Morelli G. Physicochemical properties of mixed micellar aggregates containing CCK peptides and Gd complexes designed as tumor specific contrast agents in MRI. J Am Chem Soc 2004, 126:3097-3107.
95. 3-targeted magnetic resonance imaging. Nat Med 1998, 4:623-626.
96. Storrs RW, Tropper FD, Li HY, Song CK, Kuniyoshi JK, Sipkins DA, Li KCP, Bednarski MD. Paramagnetic polymerized liposomes - synthesis, characterization, and applications for magnetic-resonance-imaging. J Am Chem Soc 1995, 117:7301-7306.